Johns Hopkins Team Pinpoints How Common Gut Bacterium Fuels Colon Cancer—and a Path to Block Its Toxin

The Bacterial Link to Colorectal Cancer

Researchers at Johns Hopkins have clarified how a widespread gut bacterium, *Bacteroides fragilis*, can promote colorectal cancer. The team identified a specific protein receptor that the bacterium’s toxin (BFT) uses to attach to colon cells, a discovery that resolves a question that has persisted since a 2009 Nature Medicine report.

Confirmed findings

• *Bacteroides fragilis* is present in up to 20 % of healthy individuals.
• Certain strains produce a toxin called B. fragilis toxin (BFT).
• BFT damages the intestinal barrier by breaking down E‑cadherin, weakening cell‑to‑cell connections.
• The receptor for BFT attachment is claudin‑4, a protein that helps form tight junctions between intestinal cells.
• A molecular decoy based on claudin‑4 sequences prevented BFT from binding to colon cells and protected mice from toxin‑induced tissue damage.

Reported claims

• The study, published in *Nature*, used CRISPR‑based genome‑wide screening to pinpoint claudin‑4.
• Senior author Cynthia Sears, M.D., described the discovery as an “exciting moment” for understanding bacterial toxin mechanisms.
• Maxwell White, an M.D./Ph.D. candidate, led the screening effort and noted that claudin‑4 was a “clear, resounding top hit.”
• The decoy approach could be refined into small molecules or biologics for future therapies.

How the Toxin Works

BFT’s harmful activity begins with attachment to colon epithelial cells. Earlier work showed that the toxin degrades E‑cadherin, a protein essential for maintaining the intestinal barrier. Without intact E‑cadherin, the protective lining becomes leaky, exposing underlying tissue to inflammatory stimuli and increasing cancer risk.

Key steps

• Attachment – BFT binds to claudin‑4 on the surface of colon cells.
• Barrier disruption – The toxin cleaves E‑cadherin, weakening cell‑cell adhesion.
• Inflammation & tumorigenesis – A compromised barrier triggers chronic inflammation, a known driver of colorectal cancer.

Identifying the Receptor with CRISPR Screening

To discover the receptor, the Johns Hopkins group performed a genome‑wide loss‑of‑function screen in colon epithelial cells. By disabling individual genes, they identified which were essential for BFT binding and toxicity. The top hit was the gene encoding claudin‑4. When this gene was turned off, BFT could no longer attach or degrade E‑cadherin.

Methodology

• CRISPR knockout library – Systematic gene inactivation across the genome.
• Assay validation – Developed a reliable assay to measure toxin attachment and damage.
• Collaboration – Worked with structural biologists at the Molecular Biology Institute of Barcelona to confirm the BFT‑claudin‑4 complex.

A Molecular Decoy Strategy

Knowing the receptor opened a therapeutic avenue. The researchers created a soluble protein containing claudin‑4 sequences that act as a decoy, diverting BFT away from real colon cells. In mouse experiments, the decoy bound the toxin, preventing it from reaching its cellular target and protecting intestinal tissue.

Potential applications

• Small‑molecule inhibitors – Mimicking the decoy’s binding interface.
• Biologic drugs – Engineered proteins with improved pharmacological properties.
• Preventive regimens – Targeting individuals colonized with high‑risk BFT‑producing strains.

Current Limitations and Unknowns

While the decoy protected mice from tissue damage, the study has not yet demonstrated that it prevents colorectal cancer in humans. Additionally, the precise three‑dimensional structure of the BFT‑claudin‑4 interaction remains unresolved, despite attempts using AI tools like AlphaFold.

Unanswered questions

• Does blocking BFT attachment reduce tumor formation in long‑term human studies?
• What are the safety profiles of decoy‑based therapies in people?
• How does the presence of multiple *Bacteroides* strains affect the efficacy of a single‑target approach?

Practical Implications

The discovery offers several actionable insights:

• Diagnostic potential – Screening for BFT‑producing *Bacteroides* strains could identify individuals at higher risk.
• Therapeutic development – Researchers can now focus on designing claudin‑4‑targeted inhibitors.
• Public health – Understanding the bacterial contribution may inform dietary or probiotic strategies to modulate gut flora.

How to Verify the Original Announcement

Interested readers can consult the primary source:

• Journal – *Nature* (2024) – the full study includes detailed methods and data.
• Institutional website – Johns Hopkins’ research portal provides press releases and supplementary materials.
• Preprint servers – If the article is posted ahead of print, check PubMed Central for the author‑corrected version.

Verification steps:

• Locate the article by title or DOI in the journal’s online archive.
• Review the authors’ affiliations (Johns Hopkins, Harvard Medical School, Molecular Biology Institute of Barcelona).
• Cross‑check any claims with the supplementary data, especially the CRISPR screen results and decoy efficacy in mouse models.

Outlook

The identification of claudin‑4 as the BFT receptor transforms a long‑standing mystery into a actionable target. Although clinical translation will require extensive safety testing, the work marks a significant step toward preventing toxin‑driven colorectal cancer and could inform broader strategies for managing bacterial contributions to gastrointestinal disease.

Keywords: colon cancer, Bacteroides fragilis, BFT, claudin‑4, CRISPR, molecular decoy, Johns Hopkins, intestinal barrier, toxin, preclinical mouse study.